Loading data
XBIONasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.98 m USD | 2.5 m USD | 2.54 m USD | 1.71 m USD | 1.16 m USD |
| Research and development expense | 3.07 m USD | 3.29 m USD | 3.49 m USD | 4.77 m USD | 3.16 m USD |
| Operating profit | -2.83 m USD | -4.2 m USD | -4.52 m USD | -6.72 m USD | -5.75 m USD |
| Income tax expense | 0 USD | 0 USD | 0 USD | 0 USD | 0 USD |
| Net income (reported basis) | -2.68 m USD | -3.96 m USD | -4.13 m USD | -6.55 m USD | -5.65 m USD |
| Basic earnings per share | -1.58 USD/share | -2.57 USD/share | -2.71 USD/share | -4.61 USD/share | -0.55 USD/share |
| Diluted earnings per share | -1.58 USD/share | -2.57 USD/share | -2.71 USD/share | -4.61 USD/share | -0.55 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.